India CROs Say DCGI Trial-Approval Switch To NDAC Too Costly
This article was originally published in PharmAsia News
Executive Summary
India's clinical-research organizations say they are taking a direct hit as a result of the decision by the Drug Controller General of India to cede its authority over clinical trials to the New-Drug Advisory Committee.